{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:05:26Z","timestamp":1793142326567,"version":"4.5.0"},"reference-count":33,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T00:00:00Z","timestamp":1503273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T00:00:00Z","timestamp":1503273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100015453","name":"Adamas Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment of levodopa\u2010induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this study was to investigate the efficacy and safety of 274 mg ADS\u20105102 (amantadine) extended\u2010release capsules (equivalent to 340\u2010mg amantadine HCl) for levodopa\u2010induced dyskinesia in a randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PD patients with \u22651 hour of troublesome dyskinesia and at least mild functional impact were randomized to placebo or ADS\u20105102 once daily at bedtime for 13 weeks. The primary efficacy analysis was based on change from baseline to week 12 on the Unified Dyskinesia Rating Scale total score in the modified intent\u2010to\u2010treat population. OFF time was a key secondary measure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At week 12, least\u2010squares mean change in the Unified Dyskinesia Rating Scale was \u221220.7 (standard error 2.2) for ADS\u20105102 (n = 37) and \u20136.3 (standard error 2.1) for placebo (n = 38; treatment difference \u221214.4, 95% confidence interval \u221220.4 to \u22128.3,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .0001), indicating improvement in levodopa\u2010induced dyskinesia. OFF time decreased 0.5 hours (standard error 0.3) for ADS\u20105102 from a baseline mean of 2.6 hours and increased 0.6 hours (standard error 0.3) for placebo from a baseline mean of 2.0 hours (treatment difference \u22121.1 hours, 95% confidence interval \u22122.0 to \u22120.2,\n                      <jats:italic>P<\/jats:italic>\n                      = .0199). The most common adverse events (ADS\u20105102 versus placebo) included dry mouth (13.5% versus 2.6%), nausea (13.5% versus 2.6%), decreased appetite (10.8% versus 0%), insomnia (10.8% versus 0%), orthostatic hypotension (10.8% versus 0%), constipation (8.1% versus 0%), falls (8.1% versus 5.3%), and visual hallucinations (8.1% versus 5.3%). Adverse events led to treatment discontinuation in 19% versus 8%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ADS\u20105102 274 mg is an oral pharmacotherapy demonstrating a significant decrease in levodopa\u2010induced dyskinesia and improving OFF time. \u00a9 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mds.27131","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T02:52:37Z","timestamp":1503283957000},"page":"1701-1709","source":"Crossref","is-referenced-by-count":156,"title":["Randomized, placebo\u2010controlled trial of ADS\u20105102 (amantadine) extended\u2010release capsules for levodopa\u2010induced dyskinesia in Parkinson's disease (EASE LID 3)"],"prefix":"10.1002","volume":"32","author":[{"given":"Wolfgang","family":"Oertel","sequence":"first","affiliation":[{"name":"Philipps University Marburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Eggert","sequence":"additional","affiliation":[{"name":"Philipps University Marburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center Kansas City Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Tanner","sequence":"additional","affiliation":[{"name":"University of California San Francisco and San Francisco Veterans Affairs Medical Center San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[{"name":"University of South Florida Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trenkwalder","sequence":"additional","affiliation":[{"name":"Paracelsus\u2010Elena\u2010Klinik, Kassel and Clinic Neurosurgery University Medical Center Goettingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Ehret","sequence":"additional","affiliation":[{"name":"Praxis Neurologie Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"Azulay","sequence":"additional","affiliation":[{"name":"H\u00f4pital de la Timone Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Parkinson's Disease and Movement Disorders Center Boca Raton Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Felt","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc. Emeryville California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jean","family":"Stempien","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc. Emeryville California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1090"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-015-1396-2"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-012-0796-9"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.06.001"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119100-00004"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-007-0718-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0205-z"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31824e8f0d"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03160070046011"},{"key":"e_1_2_8_11_1","first-page":"307","article-title":"Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease","volume":"96","author":"Silver DE","year":"1971","journal-title":"Trans Am Neurol Assoc"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.036558"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000050"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000215250.82576.87"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23829"},{"issue":"2","key":"e_1_2_8_16_1","first-page":"CD003467","article-title":"Amantadine for dyskinesia in Parkinson's disease","author":"Crosby NJ","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(71)90053-7"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(91)90113-V"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.174.4007.408"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-7634(96)00037-1"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.11.1383"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23034"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.2.226"},{"key":"e_1_2_8_24_1","volume-title":"Symmetrel (amantadine hydrochloride, USP) [prescribing information]","year":"2009"},{"key":"e_1_2_8_25_1","volume-title":"(Amantadinhydrochlorid) [Information for User\u2010In German]","author":"Amantadin STADA\u00ae","year":"2006"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(70)91211-0"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26159"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0943"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.3.181"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00003"},{"key":"e_1_2_8_31_1","doi-asserted-by":"crossref","unstructured":"HauserRA PahwaR TannerCM et al.ADS\u20105102 (amantadine) extended\u2010release capsules for levodopa\u2010induced dyskinesia in Parkinson's disease (EASE LID 2 study): interim results of an open\u2010label safety study. J Parkinsons Dis2017Aug 4 [Epub ahead of print]. doi:10.3233\/JPD-171134.","DOI":"10.3233\/JPD-171134"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.295"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.10.030"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25321"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.27131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.27131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.27131","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.27131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:05:16Z","timestamp":1786629916000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.27131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,21]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/mds.27131"],"URL":"https:\/\/doi.org\/10.1002\/mds.27131","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,21]]}}}